Respiratorius (RESP) | Spotlight

Respiratorius is a research company. Today, the company is mainly focused on development of new drug candidates for the treatment of chronic obstructive pulmonary disease (COPD), asthma and cancer. Additionally, the company focuses on project development in the area of cardiovascular diseases. The company was formed in 1999 as a spin-off from Lund University. The company is based in Lund.

Respiratorius AB

Quotes for Respiratorius AB

Right Now

+/-: 0.04
%: 3,33%
Latest: 1.24
High: 1.246
Low: 1.172
Volume: 76 443
Turnover (SEK): 93 117
Value (MSEK): 265,2

Board

CEO

Johan Drott

Chairperson of the Board

Niklas Prager

Board

Anna Törner
Ingemar Kihlström
Kristina Drott
Peter Buhl

Articles of association

News

2021-10-13 13:31:58 Produktionsstart för VAL001
2021-10-13 13:31:58 Production Initiated for VAL001
2021-10-12 08:34:00 Verifying results of efficacy for RCD405
2021-10-12 08:34:00 Verifierande resultat i effektstudie av RCD405
2021-09-29 08:32:00 Brasiliens patentverk beviljar patent för VAL001

Show More

News agencies

2021-10-13 13:59:56 Direkt: SLUTFÖRT NY FORMULERING AV VAL001
2021-10-13 13:43:40 Finwire: Respiratorius inleder produktion för VAL001
2021-10-12 08:47:03 Finwire: Respiratorius rapporterar positiva prekliniska resultat från ex vivo-studie med RCD405
2021-10-12 08:43:47 Direkt: RCD405 VISAR EFFEKT I EX VIVO-STUDIE
2021-09-29 08:41:43 Finwire: Respiratorius får patent beviljat i Brasilien

Show More

Analysis

2021-10-12 Redeye: Respiratorius: RCD405 – Verifying Efficacy Results - Redeye
2021-08-30 Redeye: Respiratorius: Patent Granted RESP9000 Series - Redeye
2021-08-09 Redeye: Respiratorius: Q2 Review
2021-07-08 Redeye: Respiratorius: Cash Injection - Redeye
2021-06-11 Redeye: Respiratorius: Changes in the board - Redeye

Videos

Upcoming reports

2021-11-10 Delårsrapport 2021-Q3
2022-02-15 Bokslutskommuniké 2021

Annual reports, prospectus etc.